William Grigg, DO
Internal Medicine · Rochester, NYNPI 1578050266
Payments from drug & device makers
Across 157 payments — averaging $338.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$24K
- Boston Scientific$21K
- Abbott$6K
- Biosense Webster, Inc.$2K
- Medical Device Business Services, Inc.$150
- Astellas Pharma US Inc$93
- plus $316 from 10 others
What the payments were for
- Grants$35,00066%
- Travel & lodging$11,78122%
- Food & beverage$5,99911%
- Education$3871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $24,142 |
| Boston Scientific | 26 | $20,740 |
| Abbott | 61 | $5,909 |
| Biosense Webster, Inc. | 18 | $1,817 |
| Medical Device Business Services, Inc. | 1 | $150 |
| Astellas Pharma US Inc | 1 | $93 |
| Biotronik Inc. | 3 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $47 |
| Johnson & Johnson | 1 | $40 |
| Cardiva Medical, Inc. | 1 | $32 |
| Amgen | 2 | $32 |
| Novartis | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Abiomed | 1 | $21 |
| Edwards Lifesciences | 1 | $16 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM MRI S-ICD$15,000
- ENSITE$2,119
- GALLANT$1,903
- Carto 3$1,524
- WATCHMAN Access System$1,409
- Farapulse$1,363
- INGEVITY MRI$1,019
- ENSITE PRECISION$398
- ADVISA DR MRI SURESCAN$185
- GENERAL - STRUCTURAL HEART$137
- AVEIR$110
How this compares
$53,166 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $35,332 |
| Metoprolol Succinate | 26 | $374 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $367 |
| ClopidogrelClopidogrel Bisulfate | 25 | $226 |
| Rosuvastatin Calcium | 24 | $215 |
| Carvedilol | 19 | $168 |
| Zolpidem Tartrate | 14 | $126 |
| Atorvastatin Calcium | 11 | $107 |
| Alprazolam | 20 | $81 |
| Clonazepam | 28 | $70 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Rochester
- Patrick ReaganRochester$9.4M
- Angela BrancheRochester$7.9M
- Patrick ConnorsRochester$4M
- Richard DunneRochester$1.6M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.